Financial Performance - Revenue for the quarter ended March 31, 2025, was $57 thousand, a slight increase from $56 thousand for the same period in 2024[10] - Total revenue for the three months ended March 31, 2025, was $57,000, a slight increase from $56,000 in the same period of 2024, representing a growth of approximately 1.79%[24] - The net income for the quarter was $21.5 million, significantly improved from a net loss of $5.0 million in the same quarter of 2024, driven by a change in fair value of warrant liability[12] - The net income for Q1 2025 was $21,490,000, compared to a net loss of $4,983,000 in Q1 2024, indicating a significant turnaround[24] - Net income per share of common stock for Q1 2025 was $2.17, compared to a loss of $5.92 per share in Q1 2024[24] Expenses - Research and development (R&D) expenses for the quarter totaled $2.5 million, up from $1.9 million in the comparable period in 2024, primarily due to increased expenses related to virology programs[10] - Research and development expenses increased to $2,506,000 in Q1 2025, up from $1,912,000 in Q1 2024, reflecting a rise of 30.96%[24] - General and administrative (G&A) expenses decreased to $2.8 million from $3.4 million in the same period in 2024, mainly due to reduced consulting fees[11] - General and administrative expenses decreased to $2,754,000 in Q1 2025, down from $3,356,000 in Q1 2024, a reduction of 17.91%[24] Assets and Liabilities - As of March 31, 2025, Traws Pharma had cash, cash equivalents, and short-term investments of approximately $15.9 million, down from $21.3 million as of December 31, 2024[9] - Total current assets decreased to $18,856,000 as of March 31, 2025, down from $24,951,000 as of December 31, 2024, a decline of 24.43%[22] - Total liabilities significantly decreased to $13,063,000 as of March 31, 2025, compared to $56,592,000 as of December 31, 2024, a reduction of 76.98%[22] - Stockholders' equity improved to $6,000,000 as of March 31, 2025, from a deficit of $31,630,000 as of December 31, 2024[22] Product Development and Regulatory Activities - Traws Pharma is preparing to submit a briefing package for ratutrelvir to regulatory authorities in Q2 2025, targeting acute COVID treatment and Long COVID prevention[6] - Tivoxavir marboxil (TXM) is positioned for a multi-billion dollar market opportunity in the U.S. for bird flu and seasonal flu treatments, with ongoing preparations for regulatory approval[7] - Phase 1 data for TXM indicated that it maintained plasma blood levels above the EC90 for approximately three weeks after a single oral dose, supporting its use as a single-dose treatment[7] - Ratutrelvir's pharmacokinetic profile showed maintenance of target blood plasma levels approximately 13 times above the EC50, indicating potential effectiveness against COVID-19[15] Strategic Initiatives - Traws Pharma is seeking partnership opportunities for its legacy oncology assets, narazaciclib and rigosertib[6] Changes in Fair Value - The change in fair value of warrant liability contributed $26,513,000 to the income statement in Q1 2025, with no comparable figure in Q1 2024[24] Shareholder Information - The weighted-average shares of common stock outstanding increased to 6,965,927 in Q1 2025, compared to 841,738 in Q1 2024, reflecting a substantial increase in shares[24]

FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-39114 Galera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 46-1454898 (State ...

Revenue and Sales Performance - Revenue of $165.6 billion increased by 2.5%, or 4.0% in constant currency (cc) [6] - Global eCommerce sales grew 22%, driven by store-fulfilled pickup & delivery and marketplace [7] - Walmart U.S. comp sales rose by 4.5%, with strong performance in health & wellness and grocery [14] - Walmart's net sales for the three months ended April 30, 2025, were $163,981 million, representing a 2.5% increase from $159,938 million in the same period of 2024 [34] - Walmart U.S. net sales for the three months ended April 30, 2025, were $112,163 million, a 3.2% increase from $108,670 million in the same period of 2024 [37] - Walmart International net sales decreased by 0.3% to $29,754 million compared to $29,833 million in the prior year [37] - Sam's Club U.S. net sales increased by 2.9% to $22,064 million from $21,435 million year-over-year [37] - Consolidated net sales for Walmart were $163,981 million, reflecting a 2.5% increase from $159,938 million in the previous year [37] - U.S. comparable sales with fuel increased by 4.4% for the 13 weeks ended May 2, 2025, compared to 3.8% in the prior year [38] Operating Income and Profitability - Operating income increased by $0.3 billion, or 4.3%, with adjusted operating income growth of 3.0% (cc) [7] - Operating income increased by 4.3% to $7,135 million for the three months ended April 30, 2025, up from $6,841 million in the prior year [34] - Adjusted operating income for the consolidated segment was $7,135 million, a 4.4% increase from $6,841 million in the same period last year [37] - Operating income for Walmart International was $1,264 million, down 17.5% from $1,533 million in the previous year [37] - Operating income for the trailing twelve months ended April 30, 2025, was $29,642 million, up from $27,613 million in 2024 [65] Cash Flow and Financial Position - Operating cash flow increased by $1.2 billion to $5.4 billion, while free cash flow rose by $0.9 billion to $0.4 billion [12] - Cash flows from operating activities for the three months ended April 30, 2025, were $5,411 million, compared to $4,249 million in 2024, indicating improved cash generation [36] - Free cash flow for the three months ended April 30, 2025, was $425 million, an increase of $852 million compared to a negative $427 million in the prior year [48] - The company experienced a net cash used in investing activities of $5,093 million for the three months ended April 30, 2025, compared to $4,409 million in 2024 [36] Membership and Other Income - Membership income grew by 14.8%, contributing to a 3.7% increase in total membership and other income [7] Inventory and Assets - Inventory increased by 3.8% to $57.5 billion, maintaining healthy in-stock levels [12] - Walmart's inventories increased to $57,467 million as of April 30, 2025, from $56,435 million at the end of January 2025 [35] - Total assets as of April 30, 2025, were $262,372 million, a slight increase from $260,823 million at the end of January 2025 [35] - Average total assets increased to $258,213 million for the trailing twelve months ended April 30, 2025, compared to $249,554 million in 2024 [63] - Total assets as of April 30, 2025, were $262,372 million, an increase from $254,054 million in 2024 [65] Net Income and Earnings Per Share - Consolidated net income attributable to Walmart decreased by 12.1% to $4,487 million for the three months ended April 30, 2025, compared to $5,104 million in 2024 [34] - Consolidated net income for the trailing twelve months ended April 30, 2025, was $19,489 million, down from $19,681 million in 2024 [63] - Reported EPS for the three months ended April 30, 2025, was $0.56, with adjusted EPS at $0.61 after accounting for unrealized and realized gains and losses [56] - For the three months ended April 30, 2024, reported EPS was $0.63, with adjusted EPS at $0.60 after adjustments for unrealized and realized gains and losses and business reorganization charges [57] Tax and Returns - The effective tax rate for the three months ended April 30, 2025, was 22.6%, adjusted to 22.8% after accounting for investment gains and losses [56] - Return on assets (ROA) decreased to 7.5% for the trailing twelve months ended April 30, 2025, down from 7.9% in 2024, primarily due to increased average total assets and a slight decline in net income [60] - Return on investment (ROI) increased to 15.3% for the trailing twelve months ended April 30, 2025, compared to 15.0% in 2024, driven by higher operating income [60] Guidance and Future Expectations - The company expects net sales for Q2 FY26 to increase by 3.5% to 4.5% in constant currency [23] - Fiscal year 2026 guidance remains unchanged, with net sales expected to be between $674.5 billion and $681 billion [27] Debt and Liabilities - The company reported a decrease in interest expense on debt by 13.1%, totaling $519 million for the three months ended April 30, 2025 [34] - Walmart's total current liabilities increased to $102,920 million as of April 30, 2025, compared to $96,584 million at the end of January 2025 [35] - Average invested capital rose to $298,082 million for the trailing twelve months ended April 30, 2025, compared to $284,415 million in 2024 [65]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 May 15, 2025 PLDT INC. (Translation of registrant's name into English) Ramon Cojuangco Building Makati Avenue, Makati City Philippines (Address of registrant's principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ SIGNA ...

English Translation of Financial Statements Originally Issued in Chinese Taiwan Semiconductor Manufacturing Company Limited and Subsidiaries Consolidated Financial Statements for the Three Months Ended March 31, 2025 and 2024 and Independent Auditors' Review Report 勤業眾信聯合會計師事務所 勤業眾信 110016 台北市信義區松仁路100號20樓 Deloitte & Touche 20F, Taipei Nan Shan Plaza No. 100, Songren Rd., Xinyi Dist., Taipei 110016, Taiwan Tel :+886 (2) 2725-9988 Fax:+886 (2) 4051-6888 www.deloitte.com.tw INDEPENDENT AUDITORS' REVIEW REPORT ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2025 Commission File No. 000-54189 MITSUBISHI UFJ FINANCIAL GROUP, INC. (Translation of registrant's name into English) 4-5, Marunouchi 1-chome, Chiyoda-ku Tokyo 100-8330, Japan (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports und ...

Clinical Development - The lead candidate bel-sar is in late-stage clinical development for primary choroidal melanoma and other solid tumors, with enrollment for the Phase 3 trial expected to complete by the end of 2025 [88]. - In a Phase 2 study, bel-sar achieved an 80% tumor control rate among Phase 3-eligible patients, with a post-treatment average growth rate of 0.011 mm/yr compared to 0.351 mm/yr prior to study entry (p<0.0001) and 90% visual acuity preservation [89]. - The ongoing Phase 1b/2 trial for non-muscle invasive bladder cancer (NMIBC) will evaluate bel-sar in approximately 26 patients, with initial data expected by year-end 2025 [93]. - The company plans to initiate a Phase 1 trial in cancers of the ocular surface in 2025, targeting an incidence rate of 35,000 patients per year in the U.S. and Europe [90]. Financial Performance - As of March 31, 2025, the company reported net losses of $27.5 million and an accumulated deficit of $401.7 million [95]. - The company has not generated any revenue since inception and does not expect to do so in the foreseeable future [99]. - Research and development expenses are expected to increase as the company continues clinical development for bel-sar and other product candidates [102]. - Research and development expenses increased to $23.3 million for the three months ended March 31, 2025, up from $17.1 million in the same period of 2024, primarily due to ongoing clinical and CRO costs associated with the global Phase 3 trial of bel-sar [109]. - General and administrative expenses rose to $5.7 million for the three months ended March 31, 2025, compared to $5.3 million in the same period of 2024, driven by higher personnel expenses [110]. - Total operating expenses for the three months ended March 31, 2025, were $29.0 million, an increase of $6.7 million from $22.3 million in the same period of 2024 [108]. - The net loss for the three months ended March 31, 2025, was $27.5 million, compared to a net loss of $19.7 million for the same period in 2024, reflecting an increase of $7.8 million [108]. Cash and Funding - The company has raised approximately $420.0 million since inception, with $99.0 million raised from the 2023 Follow-On Offering at $9.00 per share [94]. - The company had cash and cash equivalents of $128.0 million as of March 31, 2025, which is expected to fund operations into the second half of 2026 [98]. - Cash, cash equivalents, and marketable securities as of March 31, 2025, totaled $128.0 million, expected to fund operations into the second half of 2026 [118]. - Net cash used in operating activities was $23.4 million for the three months ended March 31, 2025, compared to $24.5 million for the same period in 2024 [112]. - Net cash provided by investing activities was $29.8 million for the three months ended March 31, 2025, significantly higher than $9.4 million in the same period of 2024 [115]. - The company raised approximately $420.0 million in gross proceeds through the sale of equity and convertible preferred stock up to March 31, 2025 [111]. Operating Expenses and Commitments - The company has incurred significant operating losses since 2009 and anticipates needing substantial additional funding to support ongoing operations and growth strategies [96]. - Operating lease commitments total $26.836 million, with $3.331 million due within 1 year, $10.6 million due in 1 to 3 years, and $7.598 million due in 3 to 5 years [123]. - The company has no long-term debt or finance leases, and contracts with service providers are generally cancelable [125]. - Payments due upon cancellation of contracts consist only of services provided or expenses incurred, with no material non-cancelable purchase commitments [125]. Regulatory and Accounting Matters - The company remains classified as an "emerging growth company" until it exceeds $1.235 billion in annual revenue or meets other specified criteria [129]. - The market value of the company's stock held by non-affiliates is less than $700 million, qualifying it as a "smaller reporting company" [130]. - The company has not experienced material changes to its critical accounting policies as of March 31, 2025 [126]. - No recent accounting pronouncements have had a material impact on the company's financial statements [127]. - The company has elected to use the extended transition period under the JOBS Act for compliance with new accounting standards [128]. - The company is not required to provide quantitative and qualitative disclosures about market risk due to its status as a smaller reporting company [132]. - The lease for office and laboratory space in Boston, MA, has an initial term of 10 years with a renewal option for an additional 7 years [124]. - The income tax provision for the year ended December 31, 2024, was recorded at $0.1 million, with accumulated net operating loss carryforwards of approximately $209.8 million [107]. - The company anticipates a substantial increase in expenses related to ongoing research and development activities and operating as a public company [117].

Initial Public Offering - The company generated gross proceeds of $150,000,000 from its Initial Public Offering of 15,000,000 Units at $10.00 per Unit[137]. - The company incurred $7,440,804 in transaction costs related to the Initial Public Offering, including $2,660,000 in cash underwriting fees and $4,302,000 in deferred underwriting fees[139]. Financial Position - As of March 31, 2025, the company had cash held in the Trust Account amounting to $156,875,931, which includes $3,875,931 of interest income[141]. - For the three months ended March 31, 2025, the company reported a net income of $10,378, primarily from interest earned on cash held in the Trust Account[135]. - The company has no long-term debt obligations or off-balance sheet financing arrangements as of March 31, 2025[146]. - The company incurred $60,000 in administrative service fees for the three months ended March 31, 2025, all of which was unpaid at that time[148]. Business Combination - The company plans to use substantially all funds in the Trust Account to complete its Business Combination, with remaining proceeds allocated for working capital[141]. - The Business Combination Agreement with TGE was entered into on January 27, 2025, with the company merging into TGE as a wholly-owned subsidiary[124]. - The equity value of TGE is estimated at $488,000,000, which will be divided by the total number of ordinary shares outstanding to determine the Per Share TGE Equity Value[127]. - The company has engaged Clear Street LLC and Cohen & Company Capital Markets as financial advisors for the Business Combination, with a fee of $1,500,000 payable upon completion[151]. Share Structure - The Company has two classes of shares: Class A Ordinary Shares and Class B Ordinary Shares, with net income per Ordinary Share calculated based on the weighted average shares outstanding[157]. - The diluted net income calculation excluded the effect of 5,100,000 Public Warrants and 11,120,000 Private Placement Warrants, totaling 16,220,000 shares, due to their contingent exercise[160]. Accounting and Reporting - In November 2023, the FASB issued ASU 2023-07, requiring enhanced segment reporting disclosures effective for fiscal years beginning after December 15, 2023[161]. - The Company does not anticipate that recently issued accounting standards will materially affect its unaudited condensed financial statements[162]. - The Company evaluates its financial instruments to determine if they are derivatives, with changes in fair value reported in the statement of operations[155]. Valuation of Warrants - The fair value of Public Warrants was determined using a Monte Carlo Simulation Model, with an underlying share price of $10.00 and an exercise price of $11.50[156]. - The risk-free rate used in the valuation of Public Warrants is 3.7%, with a volatility of 3.3% and a De-SPAC probability of 20.0%[156]. Registration Rights - The Company is entitled to registration rights for Founder Shares and Private Placement Warrants, allowing up to three demands for registration[153]. - The registration rights agreement stipulates that no registration will occur until securities are released from lock-up restrictions[153]. - The Company bears the expenses related to the filing of registration statements[153].

Financial Performance - For the three months ended March 31, 2025, the company reported net income of $10,378, primarily from interest earned on cash held in the Trust Account[135]. - The company has not generated any operating revenues to date and does not expect to do so until after the completion of its initial Business Combination[130]. - The company incurred $60,000 in administrative service fees for the three months ended March 31, 2025, all of which was unpaid as of that date[148]. Initial Public Offering (IPO) - The company generated gross proceeds of $150,000,000 from its Initial Public Offering of 15,000,000 Units at $10.00 per Unit[137]. - The company incurred $7,440,804 in transaction costs related to the Initial Public Offering, including $2,660,000 in cash underwriting fees and $4,302,000 in deferred underwriting fees[139]. - The underwriters were entitled to a cash underwriting discount of $0.20 per Unit, totaling $3,000,000 for the Initial Public Offering[150]. Trust Account and Business Combination - As of March 31, 2025, the company had cash held in the Trust Account amounting to $156,875,931, including $3,875,931 of interest income[141]. - The company plans to use substantially all funds in the Trust Account to complete its Business Combination, with remaining proceeds allocated for working capital[141]. - The Business Combination Agreement with TGE was entered into on January 27, 2025, with the merger expected to result in the company becoming a wholly-owned subsidiary of TGE[124]. Share Structure and Earnings Per Share - The Company has two classes of shares: Class A Ordinary Shares and Class B Ordinary Shares, with net income per Ordinary Share calculated based on the weighted average shares outstanding[157]. - The diluted net income calculation excluded the effect of 5,100,000 Public Warrants and 11,120,000 Private Placement Warrants, totaling 16,220,000 shares, due to their contingent exercise[160]. Accounting Standards and Financial Instruments - In November 2023, the FASB issued ASU 2023-07, requiring enhanced segment reporting disclosures effective for fiscal years beginning after December 15, 2023[161]. - The Company does not anticipate that recently issued accounting standards will materially affect its unaudited condensed financial statements[162]. - The Company evaluates its financial instruments to determine if they are derivatives, with changes in fair value reported in the statement of operations[155]. Valuation of Warrants - The fair value of Public Warrants was determined using a Monte Carlo Simulation Model, with an underlying share price of $10.00 and an exercise price of $11.50[156]. - The risk-free rate used in the valuation of Public Warrants is 3.7%, with a volatility of 3.3% and a De-SPAC probability of 20.0%[156]. Registration Rights - The Company is required to register securities for resale under a registration rights agreement, allowing up to three demands for registration[153]. - The registration rights agreement stipulates that no registration will occur until securities are released from lock-up restrictions[153]. - The Company bears the expenses related to the filing of registration statements[153].